Financial Data and Key Metrics Changes - Revenue for fiscal Q1 2025 was $61.4 million, a 2% decrease year-over-year from $62.6 million in fiscal Q1 2024 [19] - Adjusted EBITDA for Q1 2025 was $14 million with a margin of 22.8%, compared to $15.3 million and 24.5% margin in Q1 2024, representing an 8.7% decrease [22] - Net loss improved to $1.1 million or $0.03 per diluted share from a net loss of $1.5 million or $0.04 per diluted share in Q1 2024 [23] - Cash flow from continuing operations was $9.3 million for the three months ended December 31, 2024, compared to $10.6 million in the prior period [23] Business Line Data and Key Metrics Changes - The company completed 221,000 unique setups and deliveries in fiscal Q1 2025, a 3% increase from 215,000 in fiscal Q1 2024 [18] - Respiratory resupply setups and deliveries increased to 124,000 for the quarter, reflecting a 1% year-over-year growth [18] - Recurring revenue accounted for approximately 77% of total revenue in Q1 2025 [22] Market Data and Key Metrics Changes - The company has expanded to 135 locations across 26 states, serving over 314,000 active patients [6] - The regulatory environment remains stable, allowing for greater operational efficiency and confidence [14] Company Strategy and Development Direction - The company is focused on driving organic revenue growth, achieving operational net profit, generating positive cash flow, and expanding adjusted EBITDA and its margin [30] - Strategic initiatives include optimizing organizational structure, enhancing operational efficiencies, and exploring new market opportunities [31][32] - The company aims to leverage technology to improve operational performance and enhance workflow processes [33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about steady demand across the product portfolio and the potential for growth in calendar 2025 [35] - The company is confident in its ability to deliver exceptional patient care and strengthen relationships with payers [15] - Management noted that most headwinds from previous changes in contracts and regulations are believed to be behind them [50] Other Important Information - The company has total credit capability of $32.4 million, including $11.4 million available on a revolving credit facility [24] - The company is managing its balance sheet prudently with a net leverage ratio of 1.5x [15] Q&A Session Summary Question: Impact of contract termination on revenue - The termination of a disposable supply contract is expected to be about a $2.5 million headwind for the entire calendar year [39] Question: Headwinds from capitated contracts - The larger impact from capitated contracts will be seen in the first half of fiscal 2025, with approximately $1 million in Q2 and lesser amounts in subsequent quarters [46] Question: Progression of margins throughout the year - The company aims for steady increases in EBITDA margins as they focus on organic growth [56] Question: Resupply business traction - The company is implementing strategies to improve catchment rates and compliance, which are expected to drive growth in the resupply business [72] Question: Medicare reimbursement concerns - Management is not currently aware of any changes that would negatively impact reimbursement, and there is hope for positive news regarding the 75-25 blended rate [77] Question: Bad debt expense under GAAP - Historically, bad debt expense was around 4% to 4.5%, and improvements are expected in the second half of 2025 [80] Question: Organic growth expectations - The company is targeting a return to 8% to 10% organic growth in 2025 [82]

Financial Performance - Total revenue for the three months ended December 31, 2024, was $61,381,000, a decrease of 1.9% compared to $62,573,000 for the same period in 2023[17] - Net loss for the three months ended December 31, 2024, was $1,084,000, compared to a net loss of $1,488,000 for the same period in 2023, representing a 27.2% improvement[17] - Operating income for the three months ended December 31, 2024, was $448,000, down from $1,075,000 in the same period of 2023[17] - Total operating expenses for the three months ended December 31, 2024, were $30,398,000, an increase from $29,807,000 in the same period of 2023, reflecting a year-over-year increase of approximately 2%[62] - Adjusted EBITDA for the three months ended December 31, 2024, was $14.0 million, down from $15.3 million in the same period of 2023, reflecting a decrease of 8.6%[74] - The provision for income taxes was $30,000 for the three months ended December 31, 2024, compared to $220,000 for the same period in 2023, indicating a significant reduction of approximately 86%[63] Cash Flow and Liquidity - Cash and cash equivalents at the end of the period were $15,451,000, a decrease from $18,326,000 at the end of the same period in 2023[22] - The company experienced a net cash flow provided by operating activities of $9,300,000 for the three months ended December 31, 2024, compared to $10,606,000 for the same period in 2023[22] - Net cash flow used in investing activities increased to $3,648,000 for the three months ended December 31, 2024, up by 123.4% from $1,633,000 for the same period in 2023[101] - Net cash flow used in financing activities decreased to $5,522,000 for the three months ended December 31, 2024, down by 32.3% from $8,158,000 for the same period in 2023[102] Assets and Liabilities - Total assets as of December 31, 2024, were $242,816,000, compared to $247,248,000 as of September 30, 2024[16] - Total liabilities as of December 31, 2024, were $136,502,000, an increase from $140,057,000 as of September 30, 2024[16] - Shareholders' equity decreased to $106,314,000 as of December 31, 2024, from $107,191,000 as of September 30, 2024[16] - The total accounts payable and accrued liabilities decreased to $31,959,000 as of December 31, 2024, from $35,363,000 as of September 30, 2024, indicating a reduction of approximately 9.5%[36] Operational Metrics - The number of patients serviced increased to 157,000, up from 155,000, representing a growth of 1.3% year-over-year[74] - The cost of inventory sold was $17.8 million, representing 28.6% of revenue, a slight decrease from 28.9% in the same period of 2023[82] - The company is focused on driving organic revenue growth and expanding its presence in both existing and new markets[72] Accounting and Compliance - The Company is currently evaluating the impact of new accounting standards issued by the FASB on its consolidated financial statements and related disclosures[29] - The company reported a reduction in revenues by approximately $2,800,000 due to changes in accounting treatment, with no change to net loss[69] Legal and Regulatory Matters - The company is facing a civil investigative demand from the DOJ regarding potential false claims related to CPAP equipment, and is cooperating with the investigation[60] - The company has received a subpoena from the SEC related to the DOJ investigation, but the SEC concluded its investigation without recommending enforcement action against the company[61] Shareholder Matters - On January 25, 2025, the company received a notice from Philotimo Fund, LP regarding a proxy contest for four director candidates at the 2025 Annual General Meeting scheduled for March 17, 2025[125] - The company entered into a Non-Disclosure and Standstill Agreement with Forager Fund, L.P. on February 1, 2025, which includes a six-month standstill period preventing Forager from acquiring any equity securities or assets of the company without prior Board approval[126] - The company emphasizes that actions by activist shareholders may negatively impact its strategic plans and long-term value realization[134] - The company faces risks from proxy contests, which could disrupt operations and divert management's attention, potentially leading to loss of business opportunities and difficulties in attracting qualified personnel[134]

Exhibit 99.1 QUIPT HOME MEDICAL REPORTS FIRST QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS POSTS STRONG SEQUENTIAL IMPROVEMENT IN ADJUSTED EBITDA Cincinnati, Ohio – February 10, 2025 – Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its first quarter fiscal year 2025 financial results and operational highlights. These results pertain to the three months ended December 31, 2024 a ...

CINCINNATI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its first quarter fiscal year 2025 financial results and operational highlights. These results pertain to the three months ended December 31, 2024 and are reported in U.S. Dollars. Conference Call Quipt will host its Earnings Conference Call on Tuesday, February 11, 2025 at 10:00 a.m. ( ...

CINCINNATI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, acknowledges receipt of a notice from Philotimo Fund, LP, an entity affiliated with Kanen Wealth Management, LLC and David L. Kanen (“KWM”), purporting to provide notice of its intent to solicit proxies in support of four director candidates to the Company’s Board of Directors (the “Board”) in opposition to th ...

CINCINNATI, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal first quarter 2025 financial results on Monday, February 10, 2025, after market close. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Tuesday, February 11, 2025, at 10:00 a.m. (ET). The ca ...

Quipt Home Medical (NASDAQ: QIPT ) is one of those under-the-radar companies that answers a need in people’s daily life by delivering in-home respiratory care and durable medical equipment to 135 centers in 26 states. They’re all about respirators, and withThe mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusing on small- to mid-cap companie ...

Financial Data and Key Metrics Changes - No specific financial data or key metrics changes mentioned in the provided content [1][2][3][4] Business Line Data and Key Metrics Changes - No specific business line data or key metrics changes mentioned in the provided content [1][2][3][4] Market Data and Key Metrics Changes - No specific market data or key metrics changes mentioned in the provided content [1][2][3][4] Company Strategy and Development Direction and Industry Competition - Quipt Home Medical is a diversified healthcare services company delivering a comprehensive range of home medical equipment and services to patients across the United States [4] - The company is committed to clinical excellence powered by a patient-centric model and advanced technology-enabled solutions [4] - Quipt has expanded to over 135 locations across 26 states with over 314,000 patients [4] Management's Comments on Operating Environment and Future Prospects - No specific comments on the operating environment or future prospects mentioned in the provided content [1][2][3][4] Other Important Information - The remarks during the call include forward-looking statements that are subject to important risks and uncertainties [1] - The company's actual performance could differ materially from these statements [1] Summary of Q&A Session - No Q&A session content provided in the documents [1][2][3][4]

Quipt Home Medical Corp. (QIPT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.01. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -800%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced a loss of $0.04, delivering a surprise of -500%.Over the last four quarters, the company has surpassed ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40413 QUIPT HOME MEDICAL CORP. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (S ...